| Trial ID: | L3961 |
| Source ID: | NCT00550095
|
| Associated Drug: |
Valsartan
|
| Title: |
To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Microalbuminuria|Proteinuria
|
| Interventions: |
DRUG: valsartan
|
| Outcome Measures: |
Primary: Change in Albumin Creatinine Ratio (ACR) from baseline over a period of 24 weeks., Week 24 | Secondary: Percent reduction of (BP) at 24 weeks compared to baseline level. Percent of patients whose BP is controlled at 24 weeks (< 130/80), Week 24
|
| Sponsor/Collaborators: |
Sponsor: Novartis
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
509
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-06
|
| Completion Date: |
2009-11
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-23
|
| Locations: |
Novartis Investigative Site ,, Cairo, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT00550095
|
